Introduction: Non-infectious uveitis encompasses a group of inflammatory eye diseases that can cause irreversible vision loss if left untreated or undertreated. In cases requiring stemic treatment, a step-wise treatment approach is often employed starting with corticosteroids for severe active disease, followed by initiation of steroid-sparing therapies to maintain inflammatory control and avoid the abundant complications of long-term corticosteroid use.

Areas Covered: We review the current high-quality evidence comparing the efficacy of various systemic steroid-sparing agents in the treatment of non-infectious uveitis. For studies to be included, they had to have a prospective, randomized, comparative design or a retrospective design including at least 100 patients.

Expert Commentary: Given the rarity of uveitis and the heterogeneity of uveitic diseases, there are few randomized controlled studies that directly compare the relative efficacy of the various steroid-sparing immunosuppressive agents. Therefore, current treatment strategies are based mainly on data from observational series.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411306PMC
http://dx.doi.org/10.1080/17469899.2017.1319762DOI Listing

Publication Analysis

Top Keywords

non-infectious uveitis
12
efficacy steroid-sparing
8
steroid-sparing therapies
8
comparative efficacy
4
steroid-sparing
4
therapies non-infectious
4
uveitis
4
uveitis introduction
4
introduction non-infectious
4
uveitis encompasses
4

Similar Publications

Background: This study aimed to identify the clinical characteristics of cases that is related to the response rate of adalimumab (ADA) treatment.

Methods: A retrospective review of medical records was conducted for pediatric patients with non-infectious uveitis undergoing ADA treatment for a minimum of six months. The patients were stratified into two groups: those with anterior segment inflammation (ASI+) and those without anterior segment inflammation (ASI-).

View Article and Find Full Text PDF

Purpose: Ozurdex is a dexamethasone intravitreal implant approved for the treatment of macular edema secondary to branch or central retinal vein occlusion, non-infectious uveitis affecting the posterior segment of the eye, and diabetic macular edema.

Patients And Methods: We report a case of an accidental injection of the implant into the crystalline lens, successfully managed by surgery afterwards. The case description is supported by Anterior Segment Optical Coherence Tomography (AS-OCT) images.

View Article and Find Full Text PDF

Purpose: To evaluate the economic burden and cost-effectiveness of interventions and management of non-infectious uveitis (NIU).

Methods: A comprehensive search was conducted across Medline, Embase, and Scopus databases from inception to March 2023. Risk of bias assessments were conducted using the Joanna Briggs Institute critical appraisal tools.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!